Microrna-34a and its target genes: Key factors in cancer multidrug resistance

    Research output: Contribution to journalArticlepeer-review

    33 Citations (Scopus)


    © 2016 Bentham Science Publishers. Following the first small non-coding RNA identification in 1993, accumulated knowledge on the biogenesis, homeostasis and functional roles of micro RNAs in different physiological and patho physiological conditions has been discovered. Micro RNAs act through epigenetic regulation of gene expression. MiR-34a is a member of the MiR-34 family that is involved in p53 pathways, and is implicated in cell death/survival signaling. MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity. Deregulation of MiR-34a has been reported in several types of cancers. MiR-34a down regulation has been correlated with cancer multidrug resistance (MDR), which is a major challenge for successful cancer chemotherapy. MiR-34a mimetic agents have been shown to attenuate drug resistance in different cancer cell lines. This review focuses on the in vitro, experimental and clinical findings dealing with the role of miR-34a down regulation in MDR, and potential therapeutic opportunities arising from this role of miR-34a.
    Original languageEnglish
    Pages (from-to)933-939
    Number of pages7
    JournalCurrent Pharmaceutical Design
    Issue number7
    Publication statusPublished - 1 Feb 2016


    Dive into the research topics of 'Microrna-34a and its target genes: Key factors in cancer multidrug resistance'. Together they form a unique fingerprint.

    Cite this